COMPANY

Max Biopharma, Inc.

HQ: Los Angeles, CA source · maxbiopharma.com ↗ · West Coast

Keywords: small molecule respiratory fibrotic diseases metabolic dysfunction-associated steatohepatitis idiopathic pulmonary fibrosis

Location: Los Angeles, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

15NIH grants

Funding and NIH signals

NIH award NIH awarded $365K (SBIR Phase I 1R43HL184363-01A1, new, notice Sep 9, 2026). NIH RePORTER 1R43HL184363-01A1 (Sep 9, 2026)
Evidence (1 event)
- Sep 9, 2026 · NIH RePORTER 1R43HL184363-01A1
  Organization: MAX BIOPHARMA, INC.; City/State: LOS ANGELES, CA; Project number: 1R43HL184363-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 364853; Administering IC: National Heart Lung and Blood Institute; Project title: Examination of anti-fibrotic and immune modulatory effects of Oxy210 for targeting cystic fibrosis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 9, 2026 Grant Government grant — SBIR: $364,853 (annual award, as published), announced Sep 9, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Aug 7, 2025 Partnership Partnership / licensing announced Aug 7, 2025. Source: company's own press page. source ↗

Funding

Last 2 years.

Aug 7, 2025 Partnership / licensing announced Aug 7, 2025. Source: company's own press page. source ↗
Sep 9, 2026 Government grant — SBIR: $364,853 (annual award, as published), announced Sep 9, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗

NIH awards 15

Annual award amounts. Total $8.5M.

May 7, 2024 NIH award 5R44DK136405-02 FY2024: $889,701 awarded for that fiscal year; activity R44 (SBIR); PI PARHAMI, FARHAD; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Evaluation of anti-fibrotic and anti-infla source ↗
Apr 24, 2023 NIH award 1R44DK136405-01 FY2023: $896,990 awarded for that fiscal year; activity R44 (SBIR); PI PARHAMI, FARHAD; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Evaluation of anti-fibrotic and anti-infla source ↗
Aug 18, 2022 NIH award 5R44AR079335-02 FY2022: $852,387 awarded for that fiscal year; activity R44 (SBIR); PI PARHAMI, FARHAD; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Therapeutic Development of Osteogenic Oxys source ↗
Aug 9, 2022 NIH award 1R43HL165998-01 FY2022: $318,089 awarded for that fiscal year; activity R43 (SBIR); PI PARHAMI, FARHAD; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. An oxysterol drug candidate, Oxy210, for i source ↗
May 23, 2022 NIH award 1R43HL162245-01A1 FY2022: $320,724 awarded for that fiscal year; activity R43 (SBIR); PI PARHAMI, FARHAD; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Effect of a semi-synthetic oxysterol dru source ↗
Aug 31, 2021 NIH award 1R44AR079335-01 FY2021: $855,153 awarded for that fiscal year; activity R44 (SBIR); PI PARHAMI, FARHAD; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Therapeutic Development of Osteogenic Oxys source ↗
Aug 20, 2020 NIH award 1R43DK125139-01A1 FY2020: $223,696 awarded for that fiscal year; activity R43 (SBIR); PI PARHAMI, FARHAD; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Inhibition of Liver Fibrosis by Oxystero source ↗
May 10, 2019 NIH award 5R44AG055374-05 FY2019: $975,009 awarded for that fiscal year; activity R44 (SBIR); PI STAPPENBECK, FRANK; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Preclinical Development of Oxy200 for t source ↗
Sep 21, 2018 NIH award 2R44AG055374-04 FY2018: $975,009 awarded for that fiscal year; activity R44 (SBIR); PI STAPPENBECK, FRANK; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Preclinical Development of Oxy200 for t source ↗
May 31, 2017 NIH award 5R44AG055374-03 FY2017: $499,690 awarded for that fiscal year; activity R44 (SBIR); PI STAPPENBECK, FRANK; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Design and synthesis of bone-selective source ↗
Feb 27, 2017 NIH award 5R44AR065148-03 FY2017: $450,621 awarded for that fiscal year; activity R44 (SBIR); PI STAPPENBECK, FRANK; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Synthesis of bone-selective osteogenic source ↗
Sep 14, 2016 NIH award 9R44AG055374-02 FY2016: $498,960 awarded for that fiscal year; activity R44 (SBIR); PI STAPPENBECK, FRANK; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Design and synthesis of bone-selective source ↗
Mar 16, 2016 NIH award 2R44AR065148-02A1 FY2016: $448,646 awarded for that fiscal year; activity R44 (SBIR); PI STAPPENBECK, FRANK; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Synthesis of bone-selective osteogeni source ↗
Jul 3, 2014 NIH award 1R43AR065808-01A1 FY2014: $149,342 awarded for that fiscal year; activity R43 (SBIR); PI STAPPENBECK, FRANK; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Design and synthesis of bone-selectiv source ↗
Sep 16, 2013 NIH award 1R43AR065148-01 FY2013: $147,188 awarded for that fiscal year; activity R43 (SBIR); PI STAPPENBECK, FRANK; recipient as written: MAX BIOPHARMA, INC., LOS ANGELES, CA. Synthesis of bone-selective osteogenic source ↗